Fertility and Sterility
Volume 93, Issue 1 , Pages 174-183 , 1 January 2010

Comparison of endocrine and ultrasound profiles during ovulation induction with clomiphene citrate and letrozole in ovulatory volunteer women

  • Padma Rekha Jirge, M.R.C.O.G.

      Affiliations

    • Corresponding Author InformationReprint requests: Padma Rekha Jirge, M.R.C.O.G., Shreyas Hospital, 2013E, 6th Lane, Rajarampuri, Kolhapur, 416008, India (FAX: 00912312672388).
  • ,
  • Rajendra S. Patil, M.D.

Received 12 September 2008 ,Revised 2 October 2008 ,Accepted 3 October 2008.

References 

  1. Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab. 2006;91:760–771
  2. Adashi EY. Ovulation induction: clomiphene citrate. In:  Adashi EY,  Rock JA,  Rosenwaks Z editor. Reproductive endocrinology, surgery and technology. Lippencott-Raven: Philadelphia, PA; 1996;1:1181–1206
  3. Thessaloniki ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Consensus on infertility treatment related to polycystic ovary syndrome. Hum Reprod. 2008;23:462–477
  4. Tepper R, Lunenfeld B, Shaler J, Ovadia J, Blankstein J. The effect of clomiphene citrate and tamoxifen on cervical mucus. Acta Obstet Gynecol Scand. 1988;67:311–314
  5. Acharya U, Irvine DS, Hamilton MP, Templeton AA. The effects of three anti-oestrogen drugs on cervical mucus quality and in-vitro sperm–cervical mucus interaction in ovulatory women. Hum Reprod. 1993;8:437–441
  6. Homburg R. Clomiphene citrate—end of an era? A mini-review. Hum Reprod. 2005;8:2043–2051
  7. Homburg R, Insler V. Ovulation induction in perspective. Hum Reprod Update. 2002;8:449–462
  8. Costello MF, Emerson S, Miranda T, Bakhtyari MB, Clements S, Hughes G, et al. Case series of a single centre's treatment of ovulatory infertility with clomiphene citrate and intrauterine insemination in 2002. Aust N Z J Obstet Gynaecol. 2004;44:156–159
  9. Ratts VS, Pauls RN, Pinto AB, Kraja A, Williams DB, Odem RR. Risk of multiple gestation after ovulation induction in polycystic ovary syndrome. J Reprod Med. 2007;52:896–900
  10. Pfister CU, Martoni A, Zamagni C, Lelli G, De Braud F, Souppart C, et al. Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients. Biopharm Drug Dispos. 2001;22:191–197
  11. Mitwally MFM, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic ovarian syndrome. Reprod Technol. 2000;10:244–247
  12. Al-Fozan H, Al-Khadouri M, Tan SL, Tulandi T. A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation. Fertil Steril. 2004;82:1561–1563
  13. Garcia-Velasco JA, Moreno L, Pacheco A, Gullen A, Duque L, Requena A, et al. The aromatase inhibitor letrozole increases the concentration of intraovarian androgens and improves in vitro fertilization outcome in low responder patients: a pilot study. Fertil Steril. 2005;84:82–87
  14. Cortinez A, De Carvalho I, Vantman D, Gabler F, Iñiguez G, Vega M. Hormonal profile and endometrial morphology in letrozole-controlled ovarian hyperstimulation in ovulatory infertile patients. Fertil Steril. 2005;83:110–115
  15. Fisher SA, Reid RL, Van Vugt A, Casper RF. A randomized double-blind comparison of the effects of clomiphene citrate and the aromatase inhibitor letrozole on ovulatory function in normal women. Fertil Steril. 2002;78:280–285
  16. Fatemi HM, Kolibianakis E, Tournaye H, Camus M, Van Steirteghem AC, Devroey P. Clomiphene citrate versus letrozole for ovarian stimulation: a pilot study. Reprod Biomed Online. 2003;7:543–546
  17. Randall JM, Templeton A. Transvaginal sonographic assessment of follicular and endometrial growth in spontaneous and clomiphene citrate cycles. Fertil Steril. 2007;56:208–212
  18. Healey S, Tan SL, Tulandi T, Biljan MM. Effects of letrozole on superovulation with gonadotrophins in women undergoing intrauterine insemination. Fertil Steril. 2003;80:1325–1329
  19. Lossl K, Anderson AN, Loft A, Freiesleben NLC, Bangsboll S, Anderson CY. Androgen priming using aromatase inhibitor and hCG during early-follicular-phase GnRH antagonist down-regulation in modified antagonist protocols. Hum Reprod. 2006;21:2593–2600
  20. Mitwally MF, Casper RF, Diamond MP. The role of aromatase inhibitors in ameliorating deleterious effects of ovarian stimulation on outcome of infertility treatment. Reprod Biol Endocrinol. 2005;3:54
  21. Weil SJ, Vendola K, Zhou J, Adesanya OO, Wang J, Okafor J, et al. Androgen receptor gene expression in the primate ovary: cellular localization, regulation, and functional correlations. J Clin Endocrinol Metab. 1998;83:2479–2485
  22. Mitwally MFM, Casper RF. Aromatase inhibition reduces gonadotrophin dose required for controlled ovarian stimulation in women with unexplained infertility. Hum Reprod. 2003;18:1588–1597
  23. de Ziegler D. Associate editor's commentary: the dawning of the non-cancer uses of aromatase inhibitors in gynaecology. Hum Reprod. 2003;8:1598–1602
  24. Dafopoulos K, Kotsovassilis CG, Milingos S, Kallitsaris A, Galazios G, Zintzaras E, et al. Changes in pituitary sensitivity to GnRH in estrogen treated post-menopausal women: evidence that gonadotrophin surge attenuating factor plays a physiological role. Hum Reprod. 2004;19:1985–1992
  25. Palter SF, Tavares AB, Hourvitz A. Are estrogens of importance to primate/human ovarian folliculogenesis?. Endocrinol Rev. 2001;22:389–424
  26. Fatum M, Gyo Y, Diana P, Laufer N, Simon A. Is estradiol mandatory for an adequate follicular and embryo development? A mouse model using aromatase inhibitor (anastrozole). J Assist Reprod Genet. 2006;23:407–412
  27. Bajetta E, Martinetti A, Zilembo N, Pozzi P, La Torre I, Ferrari L, et al. Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Ann Oncol. 2002;13:1059–1066

 P.R.J. has nothing to disclose. R.S.P. has nothing to disclose.

PII: S0015-0282(08)04136-8

doi: 10.1016/j.fertnstert.2008.10.009

Fertility and Sterility
Volume 93, Issue 1 , Pages 174-183 , 1 January 2010